This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.
MTEM’s pipeline includes a number of oncology-directed assets, such as a first-generation ETB (MT-3724) in phase 2 development for pre-treated diffuse large B-cell lymphoma (DLBCL)
including diffuse large B-cell lymphoma (DLBCL). ... Novartis’ Kymriah (tisagenlecleucel) was approved soon afterwards, also gaining clearance for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
resulted in objective clinical responses in 47% of patients with mantle cell lymphoma (MCL) and 80% of patients with diffuse large B-cell lymphoma (DLBCL). ... and diffuse large B-cell lymphoma,” he added.
drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL). ... It will be made available from today for patients whose cancer has relapsed or not responded to primary
Studies have also suggested that blocking CD47 can send some tumour cells into programmed cell death (apoptosis). ... Forty Seven is also testing the drug in patients with non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and three solid tumours –
The therapy is being tested alongside Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab) in two phase 2 studies, including an investigator-led trial in patients with advanced-stage diffuse large ... B-cell lymphoma (DLBCL) and another spanning
More from news
Approximately 1 fully matching, plus 87 partially matching documents found.
The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with ... Nevertheless, European biotech has reason to be optimistic
13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... It has brought to market not one but two
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's
MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
refractory diffuse large B-cell lymphoma. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...